Articles On Cynata Therapeutics (ASX:CYP)

Highlights Cynata will present two-year patient follow-up data from its Phase 1 clinical trial of CYP-001 in SR-aGvHD at ISCT. ISCT, a major international conference, will be attended by delegates from more than 50 countries. As per...

‘More of the same’ since lunchtime saw the benchmark land at -0.25% for the day Health Care coughed up a 1.09% lift while Financials weighed heavily on -0.71% Magnum Mining wins the Small Caps trophy with +44.1% thanks to Mitsubishi deal...

Highlights Together with the placement of AU$5 million, Cynata has been able to raise total proceeds of AU$7 million Valid applications were received by CYP for AU$2.05 worth of new shares under SPP, meaning oversubscription by ~AU$0.0...

Highlights Cynata is testing the safety and efficacy of CYP-006TK in diabetic foot ulcers (DFUs), also called diabetic wounds, in an ongoing clinical trial Initial data from the first six patients is encouraging, demonstrating a notabl...

The S&P ASX 200 finished up 1.85% in April while mid and small caps outperformed their blue-chip peers Real estate topped the winning sectors for the month while tech stocks also rallied strongly in April Gold stocks continued solid ru...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Clinical-stage cell therapy company Cynata Therapeutics (ASX:CYP) has received approval from the Australian Human Research Ethics Committee to commence the proposed Phase 2 clinical trial in acute graft-versus-host disease.

Pharmaxis widens clinical trial following FDA guidance Aroa receives US FDA 510K clearance Cynata gets Australian Ethics approval to commence Phase 2   Pharmaxis to widen Phase 2 trial after FDA feedback Fibrotic diseases specialist Pharm...

Highlights Cynata previously received green light from the US FDA (Investigational New Drug application) The company also holds the Orphan Drug Status in the US for CYP-001, its lead product candidate Dr Jolanta Airey, Cynata’s Chief...

Highlights The placement of New Shares of Cynata Therapeutics is at the Offer Price of AU$0.215 per New Share The Share Purchase Plan would be available to eligible Cynata shareholders for up to AU$30,000 There is also one free attach...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX jumped 0.3% after lunch as the RBA finally kept rates on hold. XGD All Ordinaries Gold soared ~3.0% because someone missed a memo. Besra Gold is back on top with a 36% leap after Quantum’s cheque cleared customs.   Local markets w...

Highlights Cynata Therapeutics has added three new sites to the ongoing clinical trial of its compound CYP-006TK. The study targets to enrol 30 patients affected by diabetic foot ulcers (DFU). With this latest development, the company...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Cell therapy company Cynata Therapeutics (ASX:CYP) has received approval to commence the proposed phase 2 clinical trial in acute graft-versus-host disease.

Cynata Therapeutics (CYP) receives approval to launch a phase two clinical trial in acute graft-versus-host disease The clinical stage biotech company was granted the green light to undertake the trial from Advarra, a central institution...

Highlights Cynata has secured approval to start the proposed aGvHD phase 2 clinical trial in the US. The approval was granted by Advarra, Inc., a central Institutional Research Board (IRB) service provider in the USA. IRB approval is...

Cynata Therapeutics’ chief medical officer, Jolanta Airey, gives a step-by-step guide on what biotechs need to do to commence a clinical trial Which ASX biotechs have an IND submission to the FDA and will start a clinical trial soon?   Wh...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Highlights Cynata has received a Notice of Acceptance from IP Australia for a patent describing a component of its Cymerus™ MSC platform technology. The patent further bolsters the current broad and inclusive IP protection of the Cymer...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Highlights The ASX 200 benchmark index closed in green today (November 11), gaining 194.00 points or 2.79% to end at 7,158.00 points. Over the last five days, the index has gained 3.85% but is down 3.85% for the last year to date. IT...

Cynata Therapeutics (CYP) receives notice of allowance for a patent application covering its Cymerus mesenchymal stem cell (MSC) platform technologyA notice of allowance is sent to an applicant when the United States Patent and Trademark Of...

Cynata gets Notice of Allowance from US Patent Office Proteomics secures patent in Hong Kong Ramsay Healthcare and Avita gave solid quarterly updates Cynata and Proteomics’ patents update Cynata Therapeutics (ASX:CYP) rose 8pc this mornin...

Key Highlights: Cynata to collaborate with Leiden University Medical Center (LUMC) in the Netherlands, in a new clinical trial in patients who have received a kidney transplant Trial to be funded by LUMC; Cynata will supply iPSC-derived C...

Cynata Therapeutics (CYP) receives funding for its new clinical trial of Cymerus MSCs for kidney transplantationThe Leiden University Medical Centre (LUMC) agreed to fund the clinical trial investigating Cynata’s Cymerus MSCs as a treatment...

HitIQ has entered into a two-year deal with the Premier League for its concussion management tech Hearing-aid manufacturer Nuheara has been awarded two US patents Argentica Therapeutics moves to second escalated dose cohort for its stroke...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Patrys crosses blood brain barrier in health animals Cynata receives Notice of Acceptance from IP Australia Telix announces collaboration with GE Healthcare Patrys (ASX:PAB) surged 15% this morning after announcing that its full-sized deo...

Cynata Therapeutics (CYP) reveals an independent data safety monitoring board (DSMB) completes its review of the company’s diabetic foot ulcer (DFU) trialFollowing the review, the DSMB recommended that the clinical trial continue as planned...

Cynata gets green light for clinical trial from an independent review Apiam acquires large vet business in WA Cynata Therapeutics (ASX:CYP) shares surged 6% after the company announced that an independent review of its diabetic foot ulcer...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

St Vincent’s Institute of Medical Research has been awarded about $1m to investigate mesenchymal stem cells generated through Cynata Therapeutics’ proprietary Cymerus method as a treatment for heart disease.

Cynata Therapeutics (CYP) is set to investigate its Cymerus mesenchymal stem cells (MSCs) as a treatment for ischaemic heart disease (IHD) thanks to a $1 million grant from the Australian governmentThe National Health and Medical Research C...

Botanix submits NDA to the US FDA Pharmaxis reports on latest clinical trials PainChek to expand to Japan Clinical dermatology company Botanix Pharma (ASX:BOT) has submitted a New Drug Application (NDA) to the US FDA for Sofpironium Bromi...

The federal government's National Health and Medical Research Council will provide a $1 million grant to cell therapy company Cynata Therapeutics (ASX:CYP) under its Cardiovascular Health Mission.

Cell therapy company Cynata Therapeutics (ASX:CYP) has announced the appointment of Janine Rolfe as an independent non-executive director.

Avita Medical’s top line results on RECELL disappoint investors Cynata has completed a strategic review, and will terminate its Covid-19 study Resmed’s revenue grows in FY22 Shares in regenerative cells biotech Avita Medical (ASX:AVH) plu...

Cynata Therapeutics (CYP) completes a strategic review of its clinical development pipeline to maximise commercial opportunities As a result, it will conclude the current MEND respiratory distress clinical trial as COVID-19 patients admitt...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Cynata Therapeutics (CYP) receives a notice of allowance for its Cymerus mesenchymal stem from the United States Patent and Trademark Office Cymerus mesenchymal stem cell technology for treating asthma and allergic airways disease The comp...

Cynata receives notice from the US Patent Office GTG completes acquisition of AffinityDNA Dental clinic network Pacific Smiles announces earnings guidance Cell therapeutics specialist, Cynata Therapeutics (ASX:CYP), has just received a No...

Cell therapy company Cynata Therapeutics (ASX:CYP) has secured a US patent covering the use of its Cymerus mesenchymal stem cell technology in treating asthma and allergic airways disease.

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Highlights Gold prices fell sharply as the strong US dollar and rise in Treasury yields put pressure on the yellow metal. The S&P/ASX 200 Materials (Sector) XMJ was 0.323% lower at 17866.600 points on ASX at 4:12 PM AEST today. Sh...

Cynata Therapeutics, a Melbourne biotechnology company specialising in stemcell therapeutics, has linked with Sydney’s St George Hospital for a clinical trial of its proprietary respiratory product CYP-001.

Australian cell therapy company Cynata Therapeutics (ASX:CYP) has announced that St George Hospital in Sydney is now a participating site and is seeking to recruit patients in the MEND clinical trial.

Key Highlights: US FDA has cleared Cynata’s IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company Phase 2 clinical study in aGvHD expected to commence subseque...

Melbourne-based stemcell biotechnology company Cynata Therapeutics has got the green light from the USA’s Food and Drug Administration for a clinical trial to combat the deadly graft-versus-host disease.

Cynata Therapeutics (CYP) receives approval from the US Food and Drug Administration (FDA) to commence its Phase 2 clinical trial of CYP-001 CYP-001 is the company’s lead product aimed at treating patients with acute graft versus host dise...